Impact of 5-HT 3 RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 4, 2011, Pages 481-488

  Schwartzberg, Lee ^a,b   Jackson, James ^c   Jain, Gagan ^c   Balu, Sanjeev ^d   Buchner, Deborah ^d  

^a Accelerated Community Oncology Research Network   (United States)

^b WEST CLINIC   (United States)

^c XCENDA   (United States)

^d EISAI INC   (United States)

Author keywords

antiemetics; aprepitant; dexamethasone; dolasetron; granisetron; nausea; neoplasms; ondansetron; palonosetron; vomiting

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; FOSAPREPITANT; GRANISETRON; ONDANSETRON; PALONOSETRON; SEROTONIN ANTAGONIST;

ADULT; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ASSESSMENT; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SELECTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; MULTIPLE CYCLE TREATMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOQUINOLINES; LOGISTIC MODELS; MALE; MIDDLE AGED; MORPHOLINES; MULTIVARIATE ANALYSIS; NAUSEA; QUINUCLIDINES; RETROSPECTIVE STUDIES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 80051773633     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.47     Document Type: Article

References (31)

1. Aapro MS, Grunberg SM, Manikhas GM et al. A Phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol. 17(9), 1441-1449 (2006). (Pubitemid 44400384)
2. Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst. Rev. 1, CD006272 (2010).
3. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. 99-04 Palonosetron Study Group. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a Phase III, single-dose trial versus dolasetron. Cancer 98(11), 2473-2482 (2003). (Pubitemid 37466663)
4. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. 14(10), 1570-1577 (2003). (Pubitemid 37304615)
5. Kaushal J, Gupta MC, Kaushal V et al. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Singapore Med. J. 51(11), 871-875 (2010).
6. Mattiuzzi GN, Cortes JE, Blamble DA et al. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 116(24), 5659-5966 (2010).
7. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative Phase III trial. Lancet Oncol. 10(2), 115-124 (2009).
8. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann. Oncol. 15(2), 330-337 (2004). (Pubitemid 38262636)
9. Eglen RM, Lee CH, Smith WL et al. Pharmacological characterization of RS 25259-25197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br. J. Pharmacol. 114(4), 860-866 (1995).
10. Wong EH, Clark R, Leung E et al. The interaction of RS 25259-25197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br. J. Pharmacol. 114(4), 851-859 (1995).
11. Li Y, Wu X, Rojas C et al. Palonosetron uniquely inhibits substance P-mediated neuronal responses in rat nodose ganglia. Presented at: 51st American Society of Hematology Annual Meeting and Exposition. New Orleans, LA, USA, 5-8 December 2009.
12. Rojas C, Stathis M, Thomas AG et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth. Analg. 107(2), 469-478 (2008).
13. Rojas C, Thomas AG, Alt J et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur. J. Pharmacol. 626(2-3), 193-199 (2010).
14. Campos D, Pereira JR, Reinhardt RR et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol. 19(6), 1759-1767 (2001). (Pubitemid 32230878)
15. de Wit R, Herrstedt J, Rapoport B et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J. Clin. Oncol. 21(22), 4105-4111 (2003). (Pubitemid 46606177)
16. de Wit R, Herrstedt J, Rapoport B et al. The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled Phase III clinical trials. Eur. J. Cancer 40(3), 403-410 (2004). (Pubitemid 38121278)
17. Gralla RJ, de Wit R, Herrstedt J et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer 104(4), 864-868 (2005). (Pubitemid 41113689)
18. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J. Support. Oncol. 4(8), 403-408 (2006). (Pubitemid 44541016)
19. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112(9), 2080-2087 (2008). (Pubitemid 351574085)
20. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J. Clin. Oncol. 21(22), 4112-4119 (2003). (Pubitemid 46606178)
21. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al.; Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12), 3090-3098 (2003). (Pubitemid 36676265)
22. Rapoport BL, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support. Care Cancer 18(4), 423-431 (2010).
23. Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann. Oncol. 17(6), 1000-1006 (2006). (Pubitemid 43778994)
24. Takahashi T, Hoshi E, Takagi M, Katsumata N, Kawahara M, Eguchi K. Multicenter, Phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci. 101(11), 2455-2461 (2010).
25. Van Belle S, Lichinitser MR, Navari RM et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 94(11), 3032-3041 (2002). (Pubitemid 34547705)
26. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J. Clin. Oncol. 18(19), 3409-3422 (2000).
27. American Society of Clinical Oncology; Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update. J. Clin. Oncol. 24(18), 2932-2947 (2006); Erratum in: J. Clin. Oncol. 24(33), 5341-5342 (2006). (Pubitemid 46630595)
28. Roila F, Herrstedt J, Aapro M et al. ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann. Oncol. 21(Suppl. 5), v232-v243 (2010).
29. Grunberg SM, Dugan M, Muss H et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 17(5), 589-594 (2009).
30. Longo F, Mansueto G, Lapadula V et al. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer DOI: 10.1007/s00520-010-0930-x (2010) (Epub ahead of print).
31. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Antiemesis www.nccn.org (Accessed 5 February 2011)